Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 13, 2024 06:00 ET | Source: Gyre Therapeutics, Inc.

Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
October 22, 2024 16:05 ET | Source: Gyre Therapeutics, Inc.

Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis

Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
October 01, 2024 16:05 ET | Source: Gyre Therapeutics, Inc.

Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference

Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference
September 04, 2024 16:05 ET | Source: Gyre Therapeutics, Inc.

Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
August 13, 2024 06:00 ET | Source: Gyre Therapeutics, Inc.

Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
August 09, 2024 07:00 ET | Source: Gyre Therapeutics, Inc.

Gyre Therapeutics to Present at Sidoti Virtual Investor Conference

Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
August 08, 2024 16:05 ET | Source: Gyre Therapeutics, Inc.

Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors

Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
July 02, 2024 16:05 ET | Source: Gyre Therapeutics, Inc.

Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia

Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
June 18, 2024 16:05 ET | Source: Gyre Therapeutics, Inc.

Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology

Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
May 30, 2024 16:05 ET | Source: Gyre Therapeutics, Inc.

Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension

Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right